The University of Edinburgh
Effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes in Scotland
Abstract
dc:description.abstractSodium-glucose co-transporter 2 inhibitors (SGLT2i) are licensed for the treatment of type 2 diabetes (T2D). This pharmacoepidemiology PhD project investigates the effect of SGLT2i exposure in people living with T2D in Scotland, using the national patient record (Scottish Care Information (SCI)-Diabetes) which is linked to other datasets, using an observational study design. This database is ready-provisioned for research use as the Scottish Diabetes Research Network Epidemiology (SDRN-Epi) database. In this project, I explore the effect of SGLT2i exposure on continuous variable outcomes, on binary clinical event outcomes for which a beneficial effect might be expected and on potential safety outcomes. Despite SGLT2i efficacy in large cardiovascular outcome trials, there remains uncertainty about whether the treatment effect described in the randomised control trials (RCTs) extends to the population with a broader baseline cardiovascular disease (CVD) risk encountered in day-to-day practice compared to those included in the trials. There are also questions about whether the treatment effects persist in the real-world and over a longer follow-up to that studied in the RCTs. Observational pharmacoepidemiology can explore the effect of exposure in these areas. For assessing drug safety, observational pharmacoepidemiology studies remain the mainstay for investigation, as safety signals from RCTs are frequently uncertain (and they are often not powered to detect harm). In Chapter 1 (Introduction), I present a paper entitled “Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. I compare and contrast RCTs and observational pharmacoepidemiology studies and, I describe why, despite possibly being biased and confounded, observational pharmacoepidemiology studies still have merit. In Chapter 2 (Background), I show a systematic review article entitled: “Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies”. I undertook this review to explore studies similar to those I planned to undertake, and to understand the areas of uncertainty that needed to be explored. In Chapter 3 (Methods), I describe the cohort study design with prospective follow-up and the methodological approach employed in detail and the statistical analysis plan. For continuous variable outcomes, I describe an exposed-only, self-controlled study using linear mixed effect models. In these models, people act as their own controls (which cancels out the effect of time-invariant confounding) and models are fitted with an autoregressive correlation structure to reduce the effect of regression-to-the-mean and autoregressive drift. For binary clinical event outcomes, I explain how I employed different Poisson models in a cohort study with prospective follow-up to evaluate the effect of drug exposure. I then explain the difficulties that arose as I developed the pharmacoepidemiology pipeline and the methodological changes that deviated from the original statistical analysis plan I had developed and why. In Chapter 4 (Results: The association of SGLT2i exposure on continuous variable outcomes - a within-person, exposed-only cohort study), I illustrate the effect of SGLT2i exposure on a variety of biomarker outcomes. For glycosylated haemoglobin (HbA1c), I show that SGLT2i exposure was associated with a profound and sustained reduction in this variable (max -7.90 mmol/mol, 95% confidence interval (CI) -10.50, -5.28 at >102 months post-exposure). For systolic blood pressure, I show that exposure was associated with a sustained fall, up to 90-months post-exposure (max -2.28 mmHg, 95% CI -2.47, -2.09 at 18-24 months). For body mass index, exposure was associated with a sustained fall compared to pre-exposure time (max -0.52 kg/m2, 95% CI -0.54, -0.49 at 30-36 months). For estimated glomerular filtration (eGFR), SGLT2i exposure was associated with an early fall but then a protective association further out in time (max fall, -0.54 ml/min/1.73 m2, 95% CI -0.59, -0.48). For blood lipids, SGLT2i exposure was associated with a very small and likely clinically insignificant changes. In Chapter 5 (Results: The association of SGLT2i exposure on binary clinical event outcomes - a cohort study), I explore the effect of SGLT2i exposure using Poisson models. Outcomes for which a beneficial effect might be expected: for hospitalisation for heart failure, SGLT2i exposure was associated with a reduction in admissions in both the adjusted exposed/unexposed model (risk ratio (RR) 0.73, 95% CI 0.65, 0.82) and a reduction in risk that faded-in at half-maximal effect ~8 weeks post-exposure, in the fade-in Poisson model (RR 0.54, 95% CI 0.38, 0.75). For the remaining outcomes for which a beneficial effect might be expected, the exposure/outcome relationship best supported by the data was the adjusted exposed/unexposed model (which includes a possible instantaneous effect of exposure on the outcome). For PVD, although the primary effect estimate of interest did not return a positive association, the lower bound of the 95% CI were approaching one in both the adjusted exposed/unexposed and the inverseprobability of treatment weighting (IPTW) model; in the subgroup with preserved renal function, the model suggests an associated increased risk of this outcome. Potential adverse events: For diabetic ketoacidosis (DKA), the best fitting duration-response Poisson model appeared to be for a cumulative effect of exposure being associated with a lower risk of this outcome. On closer inspection of the data, it was clear that there was an apparent transient increased risk of this outcome followed by an lowering of risk, a depletion of the vulnerable effect, where those destined developed DKA did so early after exposure and had SGLT2i therapy stopped. For lower limb amputation (LLA), the primary efficacy parameter of interest suggested no association with SGLT2i exposure and LLA. It should be noted however that the lower bound of the 95% CI for in both the adjusted exposed/exposed and IPTW was approaching one. In those with reduced renal function, there was an association of increased risk in the adjusted exposed/unexposed model for LLA. For necrotising fasciitis in the whole population there was no association of increased risk but in those with reduced renal function, the IPTW model suggested increased risk. SGLT2i exposure did not appear to be associated with the following safety outcomes: hospitalisations for fractures, bladder cancer, breast cancer, urinary tract infections or hypoglycaemia. In Chapter 6 (Discussion), I summarise the findings of my studies and the important real-world confirmation and reassurance of efficacy on major cardiovascular outcomes they provide. I describe the current regulatory positions regarding SGLT2i and the literature about these medicines. I discuss in detail the difficulties of modelling exposure-outcome effects whilst minimising important potential biases and confounding, the challenge of establishing a generic pharmacoepidemiology pipeline and the lessons learned. I set out the next steps for this research, including the framework of a planned international meta-analysis following the methods already described and the other exposures to be studied (including the individual component members of the SGLT2i class).
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2023
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Caparrotta, Thomas M.
- Advisors dc:contributor.advisor
-
- Colhoun, Helen
- Webb, David
Subjects
dc:subject × 8Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/3724